These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22044070)

  • 1. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.
    Tamminen K; Huhti L; Koho T; Lappalainen S; Hytönen VP; Vesikari T; Blazevic V
    Immunology; 2012 Jan; 135(1):89-99. PubMed ID: 22044070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
    Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
    Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
    J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
    Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production, characterization and immunogenicity of P particles derived from norovirus GII.4 genotype 2004 variant.
    Su W; Gao J; Zang Y; Wu H; Wang L; Hu H; Yu X; Kong W; Jiang C
    Acta Virol; 2015 Mar; 59(1):33-9. PubMed ID: 25790049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine.
    Chen W; Kang T; Yuan R; Shao C; Jing S
    Biotechnol Lett; 2020 Jul; 42(7):1211-1218. PubMed ID: 32088791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Jan; 11(2):. PubMed ID: 30678195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and purification of norovirus virus like particles in Escherichia coli and their immunogenicity in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang W; Shen S
    Mol Immunol; 2018 Jan; 93():278-284. PubMed ID: 28802994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.
    Tamminen K; Lappalainen S; Huhti L; Vesikari T; Blazevic V
    PLoS One; 2013; 8(7):e70409. PubMed ID: 23922988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
    Malm M; Heinimäki S; Vesikari T; Blazevic V
    Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
    Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.
    Du J; Gu Q; Liu Y; Li Q; Guo T; Liu Y
    J Med Virol; 2021 Jun; 93(6):3974-3979. PubMed ID: 32869863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
    Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phylogenetic and biological characterizations of a GI.3 norovirus.
    Zheng L; Zhang H; Ma J; Liu J; Ma S; Wang M; Huo Y
    Infect Genet Evol; 2020 Nov; 85():104554. PubMed ID: 32927119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses against norovirus GII.4 virus-like particles in mice.
    Ushijima H; Machida S; Nomura A; Khamrin P; Tran DN; Nomura H; Hayakawa S
    Acta Virol; 2016; 60(4):339-346. PubMed ID: 27928912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.